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Abstract
Background: The potential for mesenchymal stem cells (MSCs) to reduce the severity
of experimental lung injury has been established in several pre-clinical studies. We have
recently demonstrated that MSCs, and MSC-secreted factors (secretome), enhance lung
repair and regeneration at 48 h following ventilation-induced lung injury (VILI). We
wished to determine the potential for MSC therapy to exert beneficial effects in the
early recovery phase following VILI when ongoing injury coexists with processes of
repair, and to compare the efficacy of MSC therapy to the use of the secretome alone.
Methods: Male Sprague–Dawley rats were anesthetized, oro-tracheally intubated, and
subjected to high stretch mechanical ventilation until lung compliance had declined by
50 % of baseline. Animals were then weaned from mechanical ventilation, and
anesthesia discontinued. Once awake and spontaneously ventilating, animals
received an intravenous injection of either rodent MSCs (10 million/kg), MSC-conditioned
medium, fibroblasts (10 million/kg), or vehicle. Thereafter, the animals were allowed to
recover and the extent of lung injury/repair was determined after 4 h.
Results: Treatment with MSCs diminished injury and enhanced recovery following VILI to
a greater extent compared to MSC-conditioned medium, with fibroblasts proving
ineffective. MSCs, but not their conditioned medium, attenuated indices of lung
injury including oxygenation, respiratory compliance, and lung edema. Total lung
water as assessed by wet:dry ratio, bronchoalveolar lavage total inflammatory
cell, neutrophil counts, and alveolar IL-6 concentrations were reduced in the
animals that received MSC therapy.
Conclusions: The immunomodulating and/or reparative effect of MSCs is evident
early after VILI in this model. MSC-conditioned medium was not as effective as the cells
themselves in diminishing injury and restoring lung structure and function.
Keywords: Acute respiratory distress syndrome; Inflammation; Ventilation-induced lung
injury; Repair; Mesenchymal stem/stromal cell
Background
The therapeutic potential of mesenchymal stem/stromal cells (MSCs) for acute respira-
tory distress syndrome (ARDS) has been demonstrated in several pre-clinical studies,
in both sepsis-induced [1–4] and non-septic [5, 6] models of ARDS. However, many
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earlier studies in pre-clinical ARDS models are limited by the fact that MSCs were
given at the time of, or even before, the induction of lung injury [1, 7]. This issue is of
critical importance to the eventual therapeutic potential of MSCs, as in the clinical set-
ting much of the injury process may be complete before the therapy can be given. A
therapy that diminishes damaging inflammation and enhances injury resolution, applied
after the injury has been induced, may therefore be more likely to translate successfully
to the bedside and to be beneficial in the clinical setting. The demonstration that MSCs
can enhance repair following severe ventilator-induced lung injury (VILI) offers consid-
erable hope for the therapeutic potential of these cells [8, 9].
An important factor in identifying the optimal timing of administration for MSCs in
ARDS is to establish the earliest time-point at which MSCs exert their beneficial effects
after injury in the lung. While our group has established that MSCs exert therapeutic
effects on lung repair when assessed 48 h after VILI, the timing of onset of benefit is
unknown. Furthermore, the precise mechanism which underlies the beneficial effects of
MSCs in ARDS remains to be determined. Several studies have reported that MSCs act
via a paracrine mechanism, with soluble factors of the MSC secretome accounting for
immunomodulatory and reparative effects [3, 4, 6, 10, 11]. In some studies, the benefi-
cial effects of MSC administration have been replicated by the MSC ‘secretome’ alone
[6, 8, 9, 12]. In contrast, other work suggests a central role for direct cell-to-cell contact
by MSCs in mediating their beneficial effects [13]. The relative importance of the differ-
ent mechanisms of action of MSCs may vary depending on the precise injury mechan-
ism and phase of the disease process.
Because of these issues, we wished to determine the potential for MSC therapy to
exert beneficial effects in the early recovery phase following VILI, and to compare the
efficacy of MSC therapy to the use of the MSC secretome alone. We hypothesized that
both MSCs and MSC-conditioned medium would diminish injury and enhance early
recovery following ventilator-induced lung injury.
Methods
All work was approved by the Animal Ethics Committee of the National University of
Ireland, Galway and conducted under license from the Department of Health, Ireland.
Specific-pathogen-free adult male Sprague–Dawley rats (Charles River Laboratories,
Kent, UK) weighing between 400 and 500 g were used in all experiments.
MSC and fibroblast culture and characterization
Rodent MSCs (MSCs) were isolated from rat femora and tibiae under sterile conditions
as previously described [14]. Briefly, male Sprague–Dawley rats (8–12 weeks old) were
euthanized by inhalation of CO2. Incisions were made on both lower limbs to expose
the tibiae and femora. Both bones were removed from the hind limbs and placed in ice
cold sterile Tyrode’s solution (Sigma, St. Louis, MO). The marrow was then flushed into
a dish containing MSC complete culture medium (MEM-α Media (Gibco, Paisley, UK),
F12-Ham Media (Gibco), 10 % fetal bovine serum (PAA, Somerset, UK), and 1 % anti-
biotic/antimycotic (Sigma) and dispersed into a cell suspension. After centrifugation and
filtration through a 100-μm nylon mesh, a cell count was performed and the cells
were transferred to a 175-cm2 flasks containing 30 ml of MSC complete medium, at a
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density of 9 × 105 cells/cm2. On day 3 of culture in an atmosphere of 5 % CO2/90 %
humidity at 37 °C, medium and non-adherent cells were removed and fresh medium
was added to each flask. Cells were ready for subculture (usually after 16–17 days)
when colonies began to exhibit a compact appearance and multi-layered growth or
when the loosely formed colonies began to merge into a monolayer (<90 % of
confluence).
Thereafter, cells were ready to be passaged after 6/7 days culture, at 80 % confluence.
For passage, media was aspirated off and cells were washed with sterile PBS to remove
any remaining serum. Eight milliliters 0.25 % trypsin/EDTA solution was added to the
cells, which were incubated for 5 min at 37 °C. The enzymatic reaction was stopped by
adding the same volume of MSC media to cells. Cells were centrifuged at 400×g for
5 min. Media was aspirated off the cell pellet which was resuspended in 1 ml and a
hemocytometer count was undertaken. Cells were expanded to passage 4, whereupon
they were used for experiments. MSC phenotype was confirmed via characterization of
cell surface markers [antibodies to CD31, CD34, CD44, CD45, CD54, CD73, and CD90,
Santa Cruz Biotechnology, Santa Cruz, CA] and analyzed with a FACScan (Becton
Dickinson, Franklin Lakes, NJ) and CellQuest software as described [15, 16].
Fibroblasts, used as control cells, were obtained from the dermis of adult Sprague–Dawley
rats as previously described [9]. Following euthanization, the skin and subcutaneous
tissue strips were excised from the ventral surface of the rat abdominal wall, placed
into 70 % ethanol for 30 s, and then placed in 0.25 % trypsin (Sigma) overnight. The
epidermis was then peeled from the dermal layer, and the dermal layer was placed on
a scored six-well plate (Sarstedt, Wexford, Ireland) in F-12/MEM-α medium supple-
mented with fetal calf serum (10 %) and penicillin/streptomycin (1 %).
MSC-conditioned medium
MSC-conditioned medium was generated from allogeneic rat MSCs (4 × 106). Briefly,
the cells were washed, the medium was replaced, and the subsequent medium without
serum for the next 24 h was used as the conditioned medium (CM). All conditioned
medium was sterile filtered through a 22-μm filter to remove cellular debris and concen-
trated using a 3000 kDa centrifugal concentrating filter (Amicon, Billerica, MA, USA) to
give 500 μl (i.e., concentrated ×30).
Rodent ventilator-induced injury protocol
We utilized our established model of repair from VILI as previously described (Fig. 1)
[8, 9, 17]. Briefly, anesthesia was induced with intraperitoneal ketamine 80 mg kg−1
(Ketalar, Pfizer, Cork, Ireland) and xylazine 8 mg kg−1 (Xylapan, Vétoquinol, Dublin,
Ireland). After confirmation of depth of anesthesia by paw clamp, intravenous access
was obtained via tail vein, laryngoscopy was performed and the animals were intubated
with a size 14G intravenous catheter (BD Insyte®, Becton Dickinson Ltd, Oxford, UK).
The lungs were ventilated using a small animal ventilator (CWE SAR 830 AP, CWE
Inc, Pennsylvania, USA). Anesthesia was maintained with repeated boli of Saffan®
(alfaxadone 0.9 % and alfadadolone acetate 0.3 %; Schering Plough, Welwyn Garden
City, UK) and muscle relaxation was achieved with cis-atracurium besylate 0.5 mg kg−1
(GlaxoSmithKline, Dublin, Ireland). Animals were subjected to injurious mechanical
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ventilation, using the following ventilator settings: Pinsp 35 cmH2O, respiratory rate
18 min−1, and PEEP 0 cmH2O until compliance decreased by 50 % of baseline. Compli-
ance was determined by incremental syringe injection of 1 ml aliquots of air over 1 s,
while simultaneously recording plateau airway pressure after each injection. Final compli-
ance was calculated by determining plateau airway pressure after 5 ml volume injection.
At this point, high stretch ventilation was discontinued and animals were extubated,
allowed to regain consciousness, and entered into the treatment protocol. Following
recovery, animals were randomized to intravenous administration of: (i) 10 × 106/kg
allogeneic rat MSCs (MSC group), (ii) 500 μl phosphate buffered saline (vehicle
group), (iii) 10 × 106/kg rat dermal fibroblasts (fibroblast group), or (iv) 500 μl of con-
ditioned medium from 10 × 106/kg allogeneic rat MSCs (MSC-CM group), in a four-
group design.
Assessment of injury and repair
Four hours following VILI induction, animals were re-anesthetized. A tracheostomy
was inserted and carotid arterial access established (22G, BD Insyte), and the lungs
were mechanically ventilated at a respiratory rate of 80 min−1, tidal volume 6 ml kg−1,
and positive end-expiratory pressure 2 cmH2O as previously described [18–20].
Intra-arterial blood pressure, peak airway pressures, and rectal temperature were
recorded continuously. Static inflation lung compliance measurements were per-
formed as previously described [18, 21]. After 20 min, the inspired gas was altered
to FiO2 of 1.0 for 15 min, and a final arterial blood sample was taken. Heparin
(400 IU kg−1, CP Pharmaceuticals, Wrexham, U.K.) was then administered intra-
venously, and animals were killed by exsanguination.
Immediately post-mortem, the heart–lung block was dissected and bronchoalveo-
lar lavage (BAL) collection was performed as previously described [20, 22]. BAL
differential cell counts were performed. Protein concentration was determined
using a Micro BCA™ Protein assay kit (Pierce, Rockford, IL, USA) [23]. BAL IL-1β,
IL-6, IL-10, and KGF concentrations were determined using quantitative sandwich
enzyme-linked immunosorbent assays (R and D Systems, Abingdon, UK) as previ-
ously described [18–20].
Fig. 1 Flow diagram indicating timelines for experimental interventions
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Lung wet:dry weight ratios were determined using the lowest lobe of the right
lung as previously described [24]. The left lung was isolated and fixed for morpho-
metric examination. Briefly, following perfusion of the pulmonary circulation with
heparinized saline, paraformaldehyde was then instilled through the pulmonary ar-
tery catheter at a pressure of 62.5 cmH2O, and the left lung inflated with parafor-
maldehyde (4 % wt vol−1) in phosphate buffered saline (300 mOsmol) at a pressure
of 25 cmH2O via the tracheal catheter for 30 min. The pulmonary artery and tra-
chea were then ligated, and the lung was stored in paraformaldehyde. The extent
of histologic lung damage was determined using quantitative stereological tech-
niques as previously described [22, 24]. Briefly, the vertical axis of each left lung
was identified and the lung was cut perpendicular to this axis into 4-mm-thick
slices, which were then embedded in paraffin and sections (7 μm) cut from each
slice, mounted on slides, and stained with hematoxylin and eosin. An image of
each complete lung section was captured, a point counting grid was superimposed
on the image, and the proportions of intra-acinar airspace and tissue determined
in 3–5 randomly chosen visual fields sampled from each section under light mi-
croscopy (×10 objective; Leica, Laboratory instruments, Wetzlar, Germany). Intra-
acinar tissue was defined as all tissues within the gas exchange portion of the lung,
i.e., respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli, including
blood vessels contained within their walls. The intra-acinar airspace was defined as
all airspaces within the lumen of respiratory bronchioles, alveolar ducts, alveolar
sacs, and alveoli.
Statistical analysis
The distribution of all data was tested for normality using Kolmogorov-Smirnov tests. Data
were analyzed by one-way ANOVA, followed by Student-Newman-Keuls, or by Kruskal-
Wallis followed by Mann–Whitney U test with the Bonferroni correction for multiple
comparisons, as appropriate. Underlying model assumptions were deemed appropriate on
the basis of suitable residual plots. A two-tailed p value of <0.05 was considered significant.
Results
Thirty-six animals were entered into the experimental protocol, with 9 allocated to
each of the 4 groups. Animals were randomly allocated into treatment groups prior to
anesthesia and VILI, by means of sealed envelopes containing group assignments. One
investigator, who was not involved in the animal experiments, was responsible for
group assignment and preparation of the cells and conditioned medium for administra-
tion. A separate investigator was responsible for physiologic measurements, as well as
estimates of inflammatory cell infiltration, histology, and cytokine ELISAs. This investi-
gator was blinded to group allocation. Three animals, one each allocated to receive
MSCs, fibroblasts, and MSC-CM group did not survive the induction of VILI and so
did not receive their allocated treatment. All other animals survived the injury protocol
and subsequent treatment allocation. There were no further deaths in the 4-h period
between receiving the treatment and the end of the protocol. There were no differences
among the groups at baseline in terms of pre-injury variables, the duration of injurious
ventilation or the extent of the lung injury produced (Table 1).
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MSCs restored lung function following VILI
Intravenous MSC therapy enhanced restoration of arterial oxygenation, as evidenced by
a reduced alveolar–arterial oxygen gradient compared to vehicle and fibroblast therapy
(Fig. 2a). MSC therapy restored respiratory system static compliance to a greater degree
than fibroblast or vehicle therapy (Fig. 2b). Compliance after 4 h remained unaltered in
the vehicle and fibroblast groups (52 ± 11 % decrease from baseline and 52 ± 2 %
decrease from baseline, respectively) versus partial restoration in the MSC group
(34 ± 13 % decrease from baseline). Of interest, MSC-CM did not restore lung physiologic
function, as measured by oxygenation (p = 0.94 vs vehicle group; p = 0.007 vs MSC group)
or lung compliance (53 ± 5 % decrease from baseline, p = 0.83 vs vehicle; p = 0.003
vs MSC group) (Fig. 2a, b). MSC therapy decreased lung wet:dry weight ratios
(Fig. 2c, p = 0.038 for MSC vs vehicle; p = 0.52 for MSC vs MSC-CM), while both
MSC and MSC-CM therapy decreased alveolar fluid protein concentrations (Fig. 2d,
p <0.001 for MSC vs vehicle and MSC-CM vs vehicle; p = 0.46 for MSC vs MSC-CM).
MSCs modulated the inflammatory response to VILI
MSC therapy decreased total inflammatory cell counts in BAL fluid (Fig. 3a) and sub-
stantially attenuated lung neutrophil accumulation (p <0.001) (Fig. 3b). In contrast,
there was no effect of MSC-CM on alveolar inflammatory cell infiltration (p = 0.14 vs
control, p = 0.06 vs MSC group) or in the number of BAL neutrophils present com-
pared to vehicle or fibroblast therapy (p = 0.128 vs vehicle, p <0.001 vs MSC group).
MSC therapy decreased alveolar concentrations of IL-1β and IL-6 (Fig. 4a, b). In con-
trast, there was no effect of MSC treatment on alveolar concentration of the anti-
inflammatory cytokine IL-10 or keratinocyte growth factor (Fig. 4c, d). MSC-CM did
not modulate the inflammatory response.
MSCs restore lung structure following VILI
MSCs decreased alveolar thickening, as evidenced by reduced alveolar tissue vol-
ume fraction, and increased recovery of airspace volume, as evidenced by
Table 1 Baseline data regarding the four groups
Variable Vehiclea Mesenchymal stem cell Conditioned medium Fibroblast therapy
Number of animals injured 9 9 9 9
Number of animals treated 9/9 8/9 8/9 8/9
Animal survival post
treatment (%)
9 (100 %) 8 (100 %) 8 (100 %) 8 (100 %)
Animal weight (g) 448 ± 19 476 ± 35 509 ± 25 450 ± 12
Duration of injurious
ventilation (min)
108 ± 39 120 ± 40 131 ± 66 101 ± 59
Lung compliance
pre-injury (ml/mmHg)
0.78 ± 0.14 0.75 ± 0.1 0.79 ± 0.14 0.74 ± 0.05
Lung compliance
immediately post-VILI
0.37 ± 0.5 0.4 ± 0.04 0.41 ± 0.05 0.37 ± 0.03
Change in compliance
from baseline (%)
50 ± 7 49 ± 4 48 ± 5 49 ± 5
Data are expressed as mean ± SD
VILI ventilation-induced lung injury
aTreatment with vehicle alone
Hayes et al. Intensive Care Medicine Experimental  (2015) 3:29 Page 6 of 14
increased alveolar airspace volume fraction (Fig. 5a, b). Representative histological
sections of lung demonstrate the greater degree of resolution of injury and alveo-
lar infiltrates in the MSC-treated animals compared to the vehicle-treated animals
(Fig. 5c, d). In contrast, there was no evidence of attenuation of structural lung
damage in the conditioned medium group compared to vehicle or fibroblast treat-
ment (Fig. 5).
Discussion
This study was designed to examine the effects of intravenous MSCs and the MSC
secretome on recovery of lung function and structure in the early phase following
lung injury induced by high stretch mechanical ventilation. Given the recently de-
scribed beneficial effects of MSCs in VILI, when administered both in the repair
phase [8, 9] and as a pre-treatment to decrease VILI development [7], we postu-
lated that MSCs would enhance recovery at an early time-point after VILI. We fur-
thermore hypothesized that the MSC secretome would have similar effects to the
cells themselves on recovery after VILI. We found that the MSC therapy enhanced
resolution of lung injury but that the secretome alone was less effective at this
stage in the recovery process.
Fig. 2 Mesenchymal stem cells attenuate physiological lung injury 4 h after VILI. Histograms representing
alveolar–arterial oxygen gradient (a), static lung compliance (b), lung wet:dry weight (c), and BAL protein
(d) 4 h following treatment. Abbreviations: Vehicle animals that received intravenous phosphate buffered
saline alone, MSC mesenchymal stem cells, MSC-CM MSC-conditioned medium, BAL bronchoalveolar lavage.
*Significantly different from vehicle control groups (P <0.05, ANOVA)
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MSCs augment early recovery following VILI
MSC therapy enhanced resolution of the lung injury as early as 4 h after VILI.
MSC-treated lungs had significantly enhanced function, as evidenced by improved
oxygenation and lung compliance, and decreased lung oedema, compared to vehicle
or fibroblast therapy. MSC therapy modulated the immune response to VILI, de-
creasing alveolar neutrophil infiltration, a major mediator of lung injury in VILI.
MSC therapy decreased alveolar concentrations of the pro-inflammatory cytokines
IL-1β and IL-6. IL-6 is among the most biologically active cytokines in the lung in
VILI [25] and has been shown to contribute to neutrophil accumulation and alveo-
lar barrier disruption [26]. Lower tidal volume ventilation, the only intervention
Fig. 3 MSCs modulate inflammation after VILI. Histogram representing bronchoalveolar lavage total white
cell count (a), and the proportion of neutrophils in the bronchoalveolar lavage (b) 4 h following treatment.
Abbreviations: Vehicle animals that received intravenous phosphate buffered saline alone, MSC mesenchymal
stem cells, MSC-CM MSC-conditioned medium, BAL bronchoalveolar lavage. *Significantly different from vehicle
control groups (P <0.05, ANOVA)
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shown to reduce mortality from ARDS, is associated with a decrease in IL-6 [27].
In the NIH/ARDSnet study, plasma levels of IL-6 in patients with ARDS were
positively correlated with mortality [28]. In contrast to our earlier studies [8, 17]
and to findings in other models [1], we found no effect of MSCs on alveolar IL-10
concentrations. However, increased production of IL-10 is not universally observed
with MSC therapy [2] and may depend on the injury mechanism and the stage of
evolution of the injury and repair processes. For example, Danchuk et al. found no signifi-
cant rise in pulmonary IL-10 in MSC-treated mice 24 and 48 h after LPS injury [29].
MSCs versus the MSC secretome for repair of the lung following VILI
In these experiments, the MSC secretome was largely ineffective in restoring lung func-
tion or structure or modulating the immune response, in the early stages following VILI.
This contrasts with the prior demonstration from our group that the MSC secretome was
as effective as MSC therapy itself in repairing the lung at 48 h following VILI [8, 9].
The original concept that MSCs could induce tissue regeneration by differentiation
into the cells of the injured organ has been largely disproven [30]. Multiple individual
paracrine factors in the MSC secretome have been demonstrated to play important
roles in mediating the effects of MSCs [12], highlighting the diverse mechanisms of ac-
tion of these cells. In our 48-h model of recovery from VILI, MSCs and their condi-
tioned medium enhanced physiologic recovery and diminished indices of inflammation
[17]. Our in vitro wound repair studies [17], and studies of alveolar fluid clearance in
Fig. 4 MSCs modulate cytokine expression 4 h after VILI. Histograms representing bronchoalveolar lavage IL-1β
(a), IL-6 (b), IL-10 (c), and KGF (d) concentrations 4 h following treatment. Abbreviations: Vehicle animals that
received intravenous phosphate buffered saline alone, MSC mesenchymal stem cells, MSC-CM MSC-conditioned
medium, BAL bronchoalveolar lavage, IL interleukin, KGF keratinocyte growth factor. *Significantly different from
vehicle control groups (P <0.05, ANOVA)
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the isolated human lung [31, 32], indicate an important role for MSC-secreted factors,
particularly Keratinocyte Growth Factor. The fact that MSCs are present only transi-
ently at the site of injury in animal models further supports this hypothesis [8]. These
findings raise the possibility that mediators released by cells could be isolated and deliv-
ered systemically or locally to treat lung injury, obviating the need to administer the
MSCs themselves.
However, the current study suggests that the MSC secretome cannot fully replicate
the effects of MSC therapy, at least in the early recovery phase following VILI. For ex-
ample, it is important to point out that MSC-CM had an effect on vascular leak, and
at least a partial effect on reducing total inflammatory cell infiltration. These findings
provide further indication of the complex mechanism of action of MSCs during injury
and repair, rather than evidence against the importance of secreted mediators. In this
regard, a number of recent insights into MSC biology should be considered. First,
MSCs have important beneficial effects that are cell contact dependent, i.e., effects
that require contact between the MSC and another cell. For example, cell-to-cell con-
tact dependent effects may interact with soluble factors to induce MSC-mediated im-
mune suppression [33], and in particular inhibition of T-cell proliferation [34] and
macrophage reprogramming to an anti-inflammatory phenotype [1]. In addition,
MSCs may enhance repair of the injured alveolar epithelium by direct mitochondrial
transfer [13]. Second, MSCs themselves may generate more stable, sustained release
Fig. 5 MSCs enhance resolution of structural lung injury 4 h after VILI. Histograms demonstrating enhanced
resolution of structural lung injury evidenced by decreased alveolar lung tissue (a) and increased alveolar
airspace fraction (b) in the MSC group. Representative photomicrographs of lung taken at a magnification
of ×10 from a PBS control (c), and MSC-treated (d), animal demonstrate greater resolution of lung injury
with MSCs at 4 h. The scale bar at the bottom right of each figure represents 200 μm
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of relevant secreted mediators at injury sites in comparison to systemic administra-
tion of individual protein factors, which may be subject to immediate metabolism in
vivo and may not reach sufficient concentrations at sites of tissue damage. Finally,
MSCs are activated by cytokines and chemokines in the injury microenvironment,
which can enhance their reparative and immunomodulatory potential [35].
We are not aware of a secreted molecule of importance that could have been re-
moved by the method we have used to produce conditioned medium and concentrate
it for in vivo use. It is important to point out that our method for conditioned medium
production and concentration is an accepted one [36] and has demonstrated a thera-
peutic effect in previous studies we have carried out [8, 17] and by other investigators
[37]. The centrifugal filters for concentration are characterized by a membrane with a
molecular weight cutoff; that is, their ability to retain molecules above a specified molecu-
lar weight. Solutes with molecular weights above 3 kDa were retained by our device,
which is considerably more sensitive than the 10-kDa filter, as used in many other studies.
Limitations
There are a number of limitations to these studies. Firstly, it is difficult to determine
whether recovery after injury constitutes solely a repair process or whether cessation of
ongoing injurious processes by cell therapy also contributes to the effect seen. Repair
after an injurious process such as VILI—reabsorption of edema fluid, alveolar epithelial
cell spreading and proliferation, plasma membrane wound sealing—occurs in conjunc-
tion with injury [38]. As such there is considerable overlap between injurious and rep-
arative processes. For example, pneumocyte proliferation and collagen synthesis occurs
early after institution of mechanical stretch-induced injury and is correlated with sur-
vival [9, 39]. However, other than removal of the injurious stimulus, it is difficult to
clearly determine which process predominates. We have based the use of the term ‘re-
covery’ on the fact that the injurious stimulus has been removed (VILI) and MSCs are
administered after a demonstrable injury has been established. While damaging inflam-
mation may be ongoing, particularly in the early phase after VILI [9], this inflammation
is necessary for an orchestrated repair response [40]. As such, injury and repair are
closely linked in this model. Secondly, caution must be exercised in extrapolating from
insights in rodent models to the clinical situation. However, these findings add to a
growing body of evidence suggesting that MSC therapy may have therapeutic potential
for ARDS. Thirdly, we did not provide baseline data on these animals, to allow the
reader to assess the magnitude of effects of injurious ventilation on the parameters
measured. However, the effect of the high stretch ventilation strategy used in this
model has been well characterized in a prior publication from our group [9]. Further-
more, we do not provide data for the effects of MSCs on protectively ventilated or un-
ventilated lungs. However, it would be expected that any effects on these uninjured
animals would be limited. Finally, we have not provided a mechanism for how benefi-
cial effects occurred in the MSC-treated group versus the conditioned medium group,
which will require further study.
Conclusions
In conclusion, we have used our established rodent model of recovery after VILI to in-
vestigate the effects of rat MSCs on early injury and repair after VILI. We have
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demonstrated that rodent MSCs, but not the MSC secretome alone, augment lung re-
pair in the early phases after VILI.
Key message
MSC therapy enhances early recovery following ventilator-induced lung injury in part
via a paracrine mechanism.
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